Transcranial ultrasound as a risk marker for Parkinson's disease
Identifieur interne : 001567 ( Istex/Corpus ); précédent : 001566; suivant : 001568Transcranial ultrasound as a risk marker for Parkinson's disease
Auteurs : Daniela BergSource :
- Movement Disorders [ 0885-3185 ] ; 2009.
English descriptors
Abstract
The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22540
Links to Exploration step
ISTEX:930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transcranial ultrasound as a risk marker for Parkinson's disease</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation><mods:affiliation>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22540</idno><idno type="url">https://api.istex.fr/document/930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001567</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Transcranial ultrasound as a risk marker for Parkinson's disease</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation><mods:affiliation>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S677">S677</biblScope><biblScope unit="page" to="S683">S683</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689</idno><idno type="DOI">10.1002/mds.22540</idno><idno type="ArticleID">MDS22540</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>neuroimaging</term><term>premotormarker</term><term>risk factor</term><term>transcranial ultrasound</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Daniela Berg MD</name><affiliations><json:string>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>transcranial ultrasound</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>risk factor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>premotormarker</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroimaging</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.169</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1498</abstractCharCount><pdfWordCount>3553</pdfWordCount><pdfCharCount>22815</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>218</abstractWordCount></qualityIndicators><title>Transcranial ultrasound as a risk marker for Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>7</total><last>S683</last><first>S677</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22540</json:string></doi><id>930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Transcranial ultrasound as a risk marker for Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Transcranial ultrasound as a risk marker for Parkinson's disease</title><author><persName><forename type="first">Daniela</forename><surname>Berg</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Hertie Institute of Clincial Brain Research, Hoppe‐Seyler‐Strasse 3, D‐72076 Tübingen, Germany</p></note><affiliation>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S677">S677</biblScope><biblScope unit="page" to="S683">S683</biblScope></imprint></monogr><idno type="istex">930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689</idno><idno type="DOI">10.1002/mds.22540</idno><idno type="ArticleID">MDS22540</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>transcranial ultrasound</term></item><item><term>Parkinson's disease</term></item><item><term>risk factor</term></item><item><term>premotormarker</term></item><item><term>neuroimaging</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-07">Received</change><change when="2009-02-19">Registration</change><change when="2009">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="145"><doi origin="wiley" registered="yes">10.1002/mds.v24.2s</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">S2</numbering></numberingGroup><coverDate startDate="2009">2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22540</doi><idGroup><id type="unit" value="MDS22540"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-07"></event><event type="manuscriptRevised" date="2009-01-05"></event><event type="manuscriptAccepted" date="2009-02-19"></event><event type="firstOnline" date="2009-10-28"></event><event type="publishedOnlineFinalForm" date="2009-10-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S677</numbering><numbering type="pageLast">S683</numbering></numberingGroup><correspondenceTo>Hertie Institute of Clincial Brain Research, Hoppe‐Seyler‐Strasse 3, D‐72076 Tübingen, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22540.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="34"></count><count type="wordTotal" number="3713"></count></countGroup><titleGroup><title type="main" xml:lang="en">Transcranial ultrasound as a risk marker for Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Transcranial Ultrasound as a Risk Marker for PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Daniela</givenNames><familyName>Berg</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="daniela.berg@uni-tuebingen.de">daniela.berg@uni‐tuebingen.de</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">transcranial ultrasound</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">risk factor</keyword><keyword xml:id="kwd4">premotormarker</keyword><keyword xml:id="kwd5">neuroimaging</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Transcranial ultrasound as a risk marker for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Transcranial Ultrasound as a Risk Marker for PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Transcranial ultrasound as a risk marker for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Daniela</namePart><namePart type="family">Berg</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurodegeneration, Center of Neurology and Hertie Institute of Clinical Brain Research, University of Tübingen, Germany</affiliation><description>Correspondence: Hertie Institute of Clincial Brain Research, Hoppe‐Seyler‐Strasse 3, D‐72076 Tübingen, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009</dateIssued><dateCaptured encoding="w3cdtf">2008-10-07</dateCaptured><dateValid encoding="w3cdtf">2009-02-19</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">34</extent><extent unit="words">3713</extent></physicalDescription><abstract lang="en">The question of early, even premotor, detection of Parkinson's disease (PD) has become a major issue because the effect of neuroprotective therapies depends on the time they are started.A number of clinical premotor markers which are helpful especially in the early diagnosis are being discussed; however, they are mostly unspecific and already signs of the progressing neurodegenerative process. An increasingly important risk marker for PD is genetic predisposition, as the number of known disease causing and modulating genes is increasing. Still, only the minority of PD cases can be attributed to monogenetic forms. Substantia nigra (SN) hyperechogenicity, assessed by transcranial sonography, has been shown to be a typical marker for PD. Because of its stability during the disease course, this echofeature is very helpful in early and differential diagnosis. Moreover, functional neuroimaging studies indicate a vulnerability of the nigrostriatal system of yet healthy subjects with SN hyperechogenicity. This vulnerability may become clinically relevant with age, under neuroleptic therapy, or under demanding motor tasks. The fact that still unaffected mutation carriers for monogenetic PD show this echofeature and that over the years some subjects with SN hyperechogenicity have already been observed to develop PD indicates that it may be regarded as a risk factor—a hypothesis which is currently being investigated in large prospective investigations. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>transcranial ultrasound</topic><topic>Parkinson's disease</topic><topic>risk factor</topic><topic>premotormarker</topic><topic>neuroimaging</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><extent unit="pages"><start>S677</start><end>S683</end><total>7</total></extent></part></relatedItem><identifier type="istex">930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689</identifier><identifier type="DOI">10.1002/mds.22540</identifier><identifier type="ArticleID">MDS22540</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001567 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001567 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:930EDACB3D7C5C9F34CB35E9C43CD8BB729B9689
|texte= Transcranial ultrasound as a risk marker for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |